Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Aaron Boudreau"'
Autor:
Faliang Wang, Cuige Zhu, Shirong Cai, Aaron Boudreau, Sun-Joong Kim, Mina Bissell, Jieya Shao
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 9 (2021)
The essential actin-binding factor profilin-1 (Pfn1) is a non-classical tumor suppressor with the abilities toboth inhibit cellular proliferation and augment chemotherapy-induced apoptosis. Besides actin, Pfn1 interacts with proteins harboring the po
Externí odkaz:
https://doaj.org/article/426870026e304906be423ad064d99cbe
Publikováno v:
PLoS ONE, Vol 9, Iss 2, p e88309 (2014)
Co-expression modules are groups of genes with highly correlated expression patterns. In cancer, differences in module activity potentially represent the heterogeneity of phenotypes important in carcinogenesis, progression, or treatment response. To
Externí odkaz:
https://doaj.org/article/46772bab9ed84c9184c6e3048737ac53
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 9 (2021)
Frontiers in Cell and Developmental Biology
Frontiers in Cell and Developmental Biology
The essential actin-binding factor profilin-1 (Pfn1) is a non-classical tumor suppressor with the abilities toboth inhibit cellular proliferation and augment chemotherapy-induced apoptosis. Besides actin, Pfn1 interacts with proteins harboring the po
Autor:
Li Wang, Jeff Settleman, Mustafa Kocak, Aaron Boudreau, David Stokoe, Amy Goodale, James Rong, Jordan Byran, Fiona E. McAllister, Josh Bittker, Todd R. Golub, Cong Zhu, Ari J. Firestone, Daphne Koller, Jordan Rossen, Kevin Larpenteur, Nicholas Eriksson, Samantha Bender, Aviad Tsherniak, Christopher C. Mader, Niclas Olsson, Colin Trepicchio, Aravind Subramanian, Jennifer Roth, Frank Li, Federica Piccioni
Publikováno v:
Molecular Cancer Therapeutics. 18:B121-B121
KEAP1-mutant non-small cell lung cancer is a high prevalence indication that responds poorly to conventional chemotherapy owing to constitutive activation of NRF2 and its associated drug metabolism target genes. Using an approach to identify compound
Autor:
Mina J. Bissell, Rohit V. Pappu, Nicholas Lyle, Jieya Shao, Shirong Cai, CJ Carey, Helen Piwnica-Worms, Marc I. Diamond, S. Joshua Swamidass, Aaron Boudreau
Publikováno v:
Journal of Biological Chemistry. 290:9075-9086
The actin-binding protein profilin-1 (Pfn1) inhibits tumor growth and yet is also required for cell proliferation and survival, an apparent paradox. We previously identified Ser-137 of Pfn1 as a phosphorylation site within the poly-l-proline (PLP) bi
Autor:
Denise M. Wolf, Anneleen Daemen, I-Spy Trial Investigators, Christina Yau, Sarah E. Davis, LJ Esserman, Lamorna Brown Swigart, L van 't Veer, Aaron Boudreau
Publikováno v:
Cancer Research. 73:P1-08
Background: Increasingly, gene expression tests are being used with standard clinicopathological markers to assess risk of recurrence in breast cancer and to guide treatment. The 70-gene signature (MammaPrint™) was recently validated in a prospecti
Autor:
Mjm Magbanua, I-Spy Trial Investigators, C. M. Haqq, Christina Yau, L.J. van 't Veer, John W. Park, Sarah E. Davis, Aaron Boudreau, Denise M. Wolf, LJ Esserman
Publikováno v:
Cancer Research. 72:P2-05
Background: Prior gene expression profiling studies have identified markers that are predictive of chemotherapy response using pre-treatment biopsies. However, this approach does not account for chemotherapy-induced perturbation in signaling within t
Publikováno v:
Cancer Research. 72:P4-09
Background: Multigene prognostic signatures derived from high-dimensional mRNA expression data have been proposed to forecast patient outcome and predict chemotherapy benefit more accurately than standard clinical parameters. However, many prognostic
Publikováno v:
Cell Adhesion & Migration. 6:236-435
The year 2011 marked the 40 year anniversary of Richard Nixon signing the National Cancer Act, thus declaring the beginning of the "War on Cancer" in the United States. Whereas we have made tremendous progress toward understanding the genetics of tum
Autor:
Christina Yau, Nola M. Hylton, Sarah E. Davis, David Haussler, Charles J. Vaske, P. Spellman, Joshua M. Stuart, Joe W. Gray, Adam B. Olshen, Ritu Roy, L van 't Veer, Aaron Boudreau, Steve Benz, LJ Esserman, Denise M. Wolf
Publikováno v:
Cancer Research. 71:P1-06
Background: A major challenge in interpreting high-throughput multianalyte genomic data sets such as those produced by the ISPY clinical trials is data integration and interpretation within the context of biologically relevant pathways. To address th